Medical Journals

Dissociated Nonsteroidal Glucocorticoid Receptor Modulators; Discovery of the Agonist Trigger in a Tetrahydronaphthalene-benzoxazine Series.

Authors:
  • Barker Mike
  • Clackers Margaret
  • Copley Royston
  • Demaine Derek A
  • Humphreys Davina
  • Inglis Graham G A
  • Johnston Michael J
  • Jones Haydn T
  • Haase Michael V
  • House David
  • Loiseau Richard
  • Nisbet Lesley
  • Pacquet Francois
  • Skone Philip A
  • Shanahan Stephen E
  • Tape Dan
  • Vinader Victoria M
  • Washington Melanie
  • Uings Iain
  • Upton Richard
  • McLay Iain M
  • Macdonald Simon J F

From: RI CEDD, GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, United Kingdom.

Journal of medicinal chemistry

  • Publish Date: Jul 2006
  • ISSN: 0022-2623
  • Volume: 49
  • Issue: 14
  • Pages: 4216-31
  • Medium: Print
  • Language: English
  • Citation (JAMA): Barker Mike, Clackers Margaret, Copley Royston, et al. Dissociated Nonsteroidal Glucocorticoid Receptor Modulators; Discovery of the Agonist Trigger in a Tetrahydronaphthalene-benzoxazine Series.. J. Med. Chem. Jul 2006;49:4216-31

Abstract

The tetrahydronaphthalene-benzoxazine glucocorticoid receptor (GR) partial agonist 4b was optimized to produce potent full agonists of GR. Aromatic ring substitution of the tetrahydronaphthalene leads to weak GR antagonists. Discovery of an “agonist trigger” substituent on the saturated ring of the tetrahydronaphthalene leads to increased potency and efficacious GR agonism. These compounds are efficacy selective in an NFkB GR agonist assay (representing transrepression effects) over an MMTV GR agonist assay (representing transactivation effects). 52 and 60 have NFkB pIC(50) = 8.92 (105%) and 8.69 (92%) and MMTV pEC(50) = 8.20 (47%) and 7.75 (39%), respectively. The impact of the trigger substituent on agonism is modeled within GR and discussed. 36, 52, and 60 have anti-inflammatory activity in a mouse model of inflammation after topical dosing with 52 and 60, having an effect similar to that of dexamethasone. The original lead was discovered by a manual agreement docking method, and automation of this method is also described.

Mesh Headings (Keywords): Administration, Topical, Animals, Anti-Inflammatory Agents, Non-Steroidal, Benzoxazines, Binding, Competitive, Cell Line, Dexamethasone, Humans, Hypersensitivity, Delayed, Mice, Models, Molecular, Radioligand Assay, Receptors, Glucocorticoid, Stereoisomerism, Structure-Activity Relationship, Tetrahydronaphthalenes, Trans-Activation (Genetics), Transcription, Genetic


Check for Full Text / PubMed Unique Identifier (PMID): 16821781


This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.

Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.

The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.


Advertisements

About | Privacy Policy | Business Solutions | Advertise | Contact | Add Healia to your site

©2012. Healia / Meredith Corporation  

Use of this site constitutes acceptance of our Terms of Service and Privacy Policy. All content on this Web site, including medical opinion and any other health-related information, is for informational purposes only and should not be used for a specific diagnosis or individual treatment plan for any situation. Use of this site and the information contained herein does not create a doctor-patient relationship. Always seek the direct advice of your doctor in connection with any questions or issues you may have regarding your own health or the health of others.